|Budget Amount *help
¥76,180,000 (Direct Cost: ¥58,600,000、Indirect Cost: ¥17,580,000)
Fiscal Year 2021: ¥15,600,000 (Direct Cost: ¥12,000,000、Indirect Cost: ¥3,600,000)
Fiscal Year 2020: ¥15,600,000 (Direct Cost: ¥12,000,000、Indirect Cost: ¥3,600,000)
Fiscal Year 2019: ¥15,600,000 (Direct Cost: ¥12,000,000、Indirect Cost: ¥3,600,000)
Fiscal Year 2018: ¥15,600,000 (Direct Cost: ¥12,000,000、Indirect Cost: ¥3,600,000)
Fiscal Year 2017: ¥13,780,000 (Direct Cost: ¥10,600,000、Indirect Cost: ¥3,180,000)
|Outline of Annual Research Achievements
We established the chemical genomics (CG) platform; CG analysis using the whole genome (WG), HET/TS and MoBY libraries and drug-resistant mutants), for which we have been writing a manuscript.
Target identification experiments have been carried out for bioactive compounds provided from the groups A01 (Dr. Hideaki Kakeya and Dr. Hirokazu Kawagishi) and A02 (Dr. Ryuichi Sakai). We screened WG/HET/TS/MoBY libraries for the collaborators’ compounds and found several candidate target genes from CG analyses using computational tools including CG-TARGET developed in collaboration with University of Minnesota. To validate drug-target interactions, we executed morphological observation upon treatment with the compounds and isolation of drug resistant mutants.
To further examine novel drug-target interactions, we employed a new set of ~10,000 compounds from the RIKEN NPDepo library, which consisted of natural products and their derivatives. First, we assessed bioactivity using the budding yeast Saccharomyces cerevisiae and identified ~380 bioactive compounds that showed >30% growth inhibition at 10 microG/mL. Next we prepared the samples for CG analysis using the HET/TS libraries. We treated the HET/TS libraries with the compounds at multiple concentrations ranging from 10 to 0.25 microG/mL and extracted DNA from the library cells. The DNA samples will be subjected to next generation sequencing for target identification.